sh-Oligopeptide-1 is a bioengineered analogue of epidermal growth factor (EGF) — a naturally occurring signalling protein documented in dermatological research for its role in supporting the skin's renewal-associated cell signalling pathways. Its effectiveness in a cosmetic formulation is inseparable from the delivery system protecting it.
What Is sh-Oligopeptide-1?
The name on an ingredient label rarely tells the whole story. sh-Oligopeptide-1 is the INCI-standardised name for a bioengineered analogue of epidermal growth factor — the protein designated EGF in biochemistry — produced via recombinant DNA technology. The prefix sh stands for synthetic human, indicating that the amino acid sequence mirrors the endogenous human EGF protein, but is manufactured outside the body using biotechnology rather than being extracted from biological tissue.
EGF was first identified and characterised by biochemist Stanley Cohen, work for which he received the Nobel Prize in Physiology or Medicine in 1986. Its biological role is that of a signalling molecule: a protein released by cells that binds to specific receptors on neighbouring cells and triggers cascades of downstream activity. In the skin, EGF signalling is associated with the regulation of keratinocyte and fibroblast behaviour — two of the most important cell populations in skin structure and renewal.
In its natural form, EGF is a 53-amino-acid polypeptide with a molecular weight of approximately 6,045 Daltons. This is significant, and we return to it in detail when discussing delivery.
- INCI name: sh-Oligopeptide-1 — the cosmetic-grade bioengineered EGF analogue
- Produced via recombinant DNA biotechnology; no extraction from human or animal tissue
- Molecular weight ~6,045 Daltons — significantly above the passive penetration threshold
- Acts via binding to EGF receptors (EGFR) on keratinocytes and fibroblasts
- Documented in in vitro research for effects on cell renewal signalling and structural protein expression
- Stability is pH- and temperature-sensitive; delivery system is a critical formulation consideration
How EGF Receptor Signalling Works
To understand what sh-Oligopeptide-1 does — and what it does not do on its own — it helps to understand how receptor-mediated signalling works in the skin.
The EGFR Pathway
Epidermal growth factor exerts its biological effects by binding to a specific transmembrane protein called the EGF receptor (EGFR), also known as ErbB1 or HER1. EGFR is expressed on the surface of keratinocytes throughout the epidermis and on fibroblasts in the dermis. When EGF binds to EGFR, the receptor undergoes a conformational change and dimerises, activating its intracellular tyrosine kinase domain.
This activation triggers downstream phosphorylation cascades — most notably through the RAS/MAPK pathway and the PI3K/AKT pathway — which regulate a range of cellular behaviours. In the context of skin, these cascades are associated with:
- Keratinocyte migration and the regulation of epidermal turnover
- Fibroblast proliferation and the upregulation of collagen, elastin, and fibronectin expression in vitro
- Regulation of matrix metalloproteinases (MMPs) — enzymes involved in extracellular matrix remodelling
- Modulation of melanocyte behaviour — relevant to discussions of post-inflammatory hyperpigmentation
It is important to be precise here. The above describes what is documented in in vitro and laboratory models of EGF signalling. The clinical evidence for topically applied sh-Oligopeptide-1 achieving these effects on intact skin is more nuanced — and that nuance is directly tied to the molecular weight problem discussed in the delivery section.
The Receptor Is on the Surface — and That Matters
A common misconception about growth factor actives is that they need to "penetrate" deeply into the skin to function. EGFR, however, is expressed across all living epidermal layers — including the upper viable epidermis, immediately below the stratum corneum. This means that receptor binding does not require deep penetration. What it does require is that the protein arrives at the skin surface intact and in a biologically relevant form — which is precisely why formulation science determines real-world effectiveness.
The EGF receptor signalling pathway is one of the most extensively characterised in cell biology. The question for skincare is not whether EGFR activation produces the documented effects — this is well established in vitro. The question is whether a topically applied peptide of 6,000 Daltons can reach its receptor sites in sufficient quantity and biological integrity to produce measurable effects at the skin surface. The answer is: it depends entirely on the delivery system.
What the Research Shows
The scientific literature on sh-Oligopeptide-1 and its parent molecule EGF is extensive — but it spans multiple research contexts that require careful distinction.
In Vitro Evidence
In controlled cell culture studies, EGF and its analogues demonstrate well-characterised effects. A study published in the Journal of Investigative Dermatology and referenced via PubMed (PMID: 2988639) documented EGF-mediated stimulation of human keratinocyte proliferation in vitro. Additional studies across fibroblast culture models have documented increases in collagen and fibronectin expression following EGFR activation — effects that are consistently replicated in laboratory conditions.
These in vitro findings are robust and form the scientific basis for including sh-Oligopeptide-1 in cosmetic formulations. However, it is standard scientific practice to distinguish in vitro evidence from clinical evidence obtained in human subjects using intact skin.
Clinical Evidence — Topical Application
Human clinical data on topically applied EGF analogues is more limited than in vitro evidence, but it exists. A randomised, double-blind clinical study (PubMed PMID: 22726639) evaluating topical EGF application documented improvements in skin smoothness and a reduction in the visible appearance of fine lines over an eight-week period. Participants with photoaged skin showed measurable outcomes, with the study authors noting that effects were associated with EGF's influence on epidermal renewal-related signalling pathways.
It is worth noting that the results in clinical studies are consistently described as improvements in visible appearance — consistent with the cosmetic claim framework — rather than structural changes quantified by biopsy. This is the appropriate standard for topical cosmetic ingredients, and it reflects an accurate reading of what is achievable via topical application.
- In vitro: EGFR-mediated keratinocyte and fibroblast signalling — extensively documented
- In vitro: Collagen, elastin, and fibronectin expression associated with EGF receptor activation
- In vitro: MMP modulation in response to EGFR pathway activation
- Clinical (topical): Improvements in visible skin smoothness and texture in human subjects
- Clinical (topical): Reduced visible appearance of fine lines in photoaged skin over 8 weeks
- Individual results vary; formulation quality and delivery method are significant determinants
Why Delivery Is Everything for EGF
Of all the topics in cosmetic peptide science, delivery is the most consequential — and the most frequently overlooked on product labels and marketing materials.
The 500 Dalton Rule
The 500 Dalton rule, first systematically described in dermatological literature, establishes that molecules with a molecular weight above approximately 500 Daltons do not passively penetrate the intact stratum corneum to a meaningful extent. At ~6,000 Daltons, sh-Oligopeptide-1 is twelve times above this threshold.
This does not mean EGF has no role in topical skincare — EGFR is expressed in the upper viable epidermis, directly below the stratum corneum, and the stratum corneum is not entirely impermeable. But it does mean that a simple aqueous serum carrying unencapsulated sh-Oligopeptide-1 will have a fraction of the receptor availability of a well-formulated encapsulated system — because most of the peptide will remain in the product film on the skin surface rather than reaching receptor-bearing cell populations.
The Stability Problem
sh-Oligopeptide-1 is a thermally and enzymatically sensitive molecule. It degrades at elevated temperatures, is inactivated by extremes of pH, and is subject to proteolytic breakdown — meaning skin-surface proteases and enzymes in the formulation itself can render it inactive before it exerts any receptor-binding activity. A peptide that degrades before reaching its target is, for practical purposes, absent from the formulation.
This is why an encapsulated delivery system — one that protects the peptide from environmental degradation, controls its release at the skin surface, and supports its biological integrity on arrival — is not a marketing enhancement but a functional requirement for effective EGF delivery.
The presence of sh-Oligopeptide-1 on an ingredient list does not guarantee efficacy. The questions that determine performance are: Is the peptide stabilised against thermal and enzymatic degradation? Is it protected from the formulation environment during storage? And is it delivered to the skin surface in a form that supports receptor availability? A peptide present in an unstable free form will not perform equivalently to one delivered via a validated encapsulation system — regardless of concentration.
EGF vs Other Renewal Actives
Understanding where sh-Oligopeptide-1 sits relative to other well-studied renewal ingredients helps clarify its distinct mechanism and the contexts in which it is most valuable.
A key point from the comparison above: EGF and PDRN are not competing actives. They operate through distinct receptor systems — EGFR versus adenosine A2A receptors — and are documented in research to support overlapping but non-identical aspects of skin renewal. Their co-formulation, when properly stabilised and delivered, is a scientifically reasoned approach rather than formulation redundancy.
Common Misconceptions
This overstates the penetration barrier while understating the role of delivery technology. EGFR is expressed in the upper viable epidermis — directly adjacent to the stratum corneum — not only in the deep dermis. A well-formulated, encapsulated sh-Oligopeptide-1 system is designed for surface receptor availability, not dermal penetration. The published clinical data on topical EGF does show measurable outcomes in human subjects.
Concentration is secondary to stability and delivery. An unencapsulated sh-Oligopeptide-1 at 5% that degrades during shelf life will underperform a properly stabilised, encapsulated system at 0.5%. The questions to ask of any EGF product are about formulation science, not headline percentage.
Correct. The sh prefix in the INCI name confirms synthetic human origin — meaning the amino acid sequence is identical to endogenous human EGF but the molecule is produced via recombinant fermentation. This removes any concerns about tissue-source safety and allows consistent batch purity.
Skin Types & Suitability
sh-Oligopeptide-1 has a broad skin-type compatibility profile. Unlike retinoids — which carry photosensitisation risk and require acclimatisation periods — EGF analogues act via a receptor-specific mechanism without the exfoliation effects that can cause initial sensitivity.
- Mature and photoaged skin: documented in research for support of skin renewal signalling associated with chronological and environmental ageing
- Skin showing early signs of ageing: most associated with improved visible smoothness and texture over consistent use
- Combination and oily skin: sh-Oligopeptide-1 does not contribute to pore occlusion; its signalling effects are receptor-mediated
- Sensitive skin: generally well tolerated, though as with any active, gradual introduction is advisable for reactive skin types
- South Asian and Indian skin tones: relevant due to EGF's documented association with melanocyte signalling — formulations combining EGF with pigmentation-modulating actives such as niacinamide are particularly well suited to this concern
Use with caution if: you are currently experiencing an active inflammatory skin condition. While sh-Oligopeptide-1 is not a primary irritant, compromised barrier function alters the skin environment in ways that can affect how any active is experienced. Prioritising barrier repair before introducing renewal actives is the recommended sequencing approach — consistent with the principle outlined in our TEWL and barrier science guide.
07 — Routine UseRoutine Use & Ingredient Combinations
Where It Sits in a Routine
sh-Oligopeptide-1 is typically formulated in the serum step — after cleansing and toning, before moisturising. As a signalling peptide, it benefits from direct skin contact and a stable pH environment (typically pH 5.0–6.5 for EGF stability). Applying it to damp skin can support contact and absorption dynamics.
Avoid combining in the same step with:
- High-concentration AHAs/BHAs — low-pH environments (below pH 4) may compromise EGF stability
- Retinoids at high concentration — not due to ingredient incompatibility per se, but because combining multiple high-activity renewal signals in one step introduces unnecessary complexity for the skin to process
Evidence-Supported Combinations
- sh-Oligopeptide-1 + PDRN: complementary receptor systems (EGFR + adenosine A2A); both associated with renewal signalling — the research basis for their co-formulation in SkinReset™
- sh-Oligopeptide-1 + Adenosine: adenosine's A2A receptor activation complements EGFR signalling; further supports the skin's natural renewal environment
- sh-Oligopeptide-1 + Niacinamide: niacinamide supports barrier function and sebum regulation; provides a stable, tolerability-supporting base for EGF's renewal signalling
- sh-Oligopeptide-1 + Sodium Hyaluronate: hydration maintenance supports the skin environment in which EGF receptor activity occurs; HA does not interfere with EGFR binding
08 — FAQ
Frequently Asked Questions
sh-Oligopeptide-1 is the INCI (International Nomenclature of Cosmetic Ingredients) name for a bioengineered analogue of epidermal growth factor (EGF). Produced via recombinant DNA biotechnology with a synthetic human amino acid sequence, it is documented in dermatological research for supporting the skin's natural renewal-associated cell signalling pathways via EGF receptor (EGFR) binding.
In laboratory studies, sh-Oligopeptide-1 binds to EGFR on keratinocytes and fibroblasts, triggering signalling cascades associated with cell renewal, fibroblast activity, and the expression of structural proteins. In topical cosmetic use, published clinical studies document improvements in the visible appearance of skin texture and smoothness over consistent application. Individual results vary and are significantly influenced by the delivery system used.
sh-Oligopeptide-1 is an approved cosmetic ingredient under the EU Cosmetic Regulation (EC) No 1223/2009 and is widely used in global cosmetic formulations. Its synthetic human origin means it is free from tissue-sourcing concerns. It is generally well tolerated across skin types; those with reactive or compromised barrier skin should introduce it gradually.
At ~6,000 Daltons, sh-Oligopeptide-1 is well above the 500 Dalton passive permeation threshold. It is also sensitive to heat and enzymatic degradation, meaning unprotected peptide in a standard aqueous formulation may degrade before meaningful receptor availability is achieved. Encapsulation technologies that stabilise and protect the peptide — and support its availability at receptor-bearing cell populations — are a functional formulation requirement, not a cosmetic enhancement.
Yes. sh-Oligopeptide-1 and PDRN operate via distinct receptor pathways — EGFR and adenosine A2A receptors respectively — making them complementary rather than redundant. Research models suggest the two pathways both support fibroblast activity and skin renewal through different mechanisms. Their co-formulation, when stabilised and delivered appropriately, is a well-supported approach in dermatological research.
In published research, sh-Oligopeptide-1 is associated with support for the visible appearance of skin texture, smoothness, and fine lines. It has also been studied in relation to skin experiencing environmental and photodamage-related stress. Its documented activity on melanocyte signalling pathways makes it of particular relevance for combination formulations targeting uneven skin tone.
SkinReset™ PDRN Serum combines sh-Oligopeptide-1 with 3000ppm encapsulated PDRN, 5% niacinamide, adenosine, and a multi-molecular weight hyaluronic acid complex — all delivered via a patent-pending Dual Encapsulation Delivery Technology with confirmed particle sizes between 100nm and 175nm — designed to support the biological availability of every active it carries.
SkinReset™ PDRN Serum
3000ppm encapsulated PDRN · sh-Oligopeptide-1 (EGF) · 5% Niacinamide · Adenosine · Multi-MW Hyaluronic Acid Complex — delivered via patent-pending Dual Encapsulation Delivery Technology.
Explore SkinReset™ →This article is written for educational purposes and reflects published scientific and dermatological research. It does not constitute medical advice. Individual results vary. The ingredient information presented relates to the active in isolation and in peer-reviewed literature; product performance depends on formulation, concentration, and delivery system. Boldpurity products are cosmetic formulations and are not intended to diagnose, treat, cure, or prevent any disease or medical condition.
